UFPT
UFP Technologies Inc
$320.04
▲ 1.9%Updated Today 11:10 AM ET
UFPT at a glance — five pillars scored 0–100 from real filed financials.
Overall: Unrated · 0/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
Market Cap
$0.00
P/E
—
Forward P/E (est.)
—
ROE
—
Revenue Growth
—
EPS Growth
—
Profit Margin
—
FCF Yield
—
Debt / Equity
—
ROIC
13.0%
Interest Coverage
11.45x
Current Ratio
3x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
0/100
UFP Technologies Inc (UFPT) is a small-cap company in the Health Care industry, part of the Health Care sector of the S&P 500.
In its latest reported year it generated about $602.80M in revenue and $68.31M in net profit.
Our model rates UFPT Unrated (0/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
2Y CAGR
22.7%
Revenue moved from $400.07M in 2023 to $602.80M in 2025, a 22.7% compound annual growth rate. The most recent year was roughly steady year over year. Slower, mature growth is common for established businesses.
Gross Margin
28.3%
Operating Margin
15.3%
Net Margin
11.3%
ROE
—
Total Debt
$117.31M
Net Debt
$108.26M
Net Debt / EBITDA
1.17x
Debt / Equity
—
Leverage: debt-to-equity is n/a, and operating profit covers interest about 11.4x, with a current ratio of 3.0x. Detailed balance-sheet leverage is limited for this name. It carries roughly $117.31M of total debt against $9.04M of cash.
Operating CF
$91.91M
Free Cash Flow
$91.91M
FCF Margin
15.2%
In the latest year UFP Technologies Inc produced about $91.91M of operating cash flow and $91.91M of free cash flow after capital spending. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
—
P/S
—
P/B
—
EV / EBITDA
—
UFPT trades at n/a trailing earnings. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where UFPT sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How UFPT stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), UFPT ranks #308 of 324 by our overall rating.
P/E vs sector
—
median 27.3x
ROE vs sector
—
median 14.1%
Growth vs sector
—
median 7.6%
Sector rank
#308
of 324 by rating
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $320.04 today · expected CAGR -14% – -5%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $651.02M | $703.10M | $759.35M | $820.10M | $885.71M |
| Net income | $71.61M | $77.34M | $83.53M | $90.21M | $97.43M |
| EPS | $9.25 | $9.98 | $10.78 | $11.65 | $12.58 |
| Share price (low) | $110.94 | $119.82 | $129.40 | $139.76 | $150.94 |
| Share price (high) | $184.91 | $199.70 | $215.67 | $232.93 | $251.56 |
| CAGR (low–high) | -65% / -42% | -39% / -21% | -26% / -12% | -19% / -8% | -14% / -5% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for UFPT:
- As an established S&P 500 member in Health Care, it brings scale and a long operating history.
The case against UFPT:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the picture is mixed: UFP Technologies Inc is a small-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Unrated (0/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 10 Wall Street analysts covering UFPT recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
UFPT's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
UFPT — frequently asked questions
Is UFPT a good stock to buy?
We don't give buy or sell advice. Review UFP Technologies Inc's fundamentals, valuation, and 5-year financials on this page, then make your own decision — and consider a licensed professional.
Where does UFPT's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from UFP Technologies Inc's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for UFPT calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this UFPT analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell UFPT. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.